Lincoln, Nebraska, May 25, 2023 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, July 14, 2023, to shareholders of record as of the close of business on Friday, June 30, 2023.
For more than 40 years, NRC Health has been committed to achieving Human Understanding and bringing healthcare organizations closer to their customers than ever before by illuminating and improving the key moments that define an experience and build trust. Guided by their uniquely empathic heritage, proprietary methods, skilled associates, and holistic approach, NRC Health helps its customers design experiences that exceed expectations, inspire loyalty, and improve well-being among patients, residents, physicians, nurses, and staff.
| Last Trade: | US$17.76 |
| Daily Change: | -0.08 -0.45 |
| Daily Volume: | 50,447 |
| Market Cap: | US$417.000M |
October 25, 2024 August 22, 2024 August 06, 2024 May 07, 2024 February 13, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
